new glp 1 agonist A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure Current Insights, Advantages and Challenges
Description
It is worth highlighting that owing to the unique physiological properties of biologics, including stability, specificity, selectivity and ability to block specific protein-protein interactions, the biologics segment is likely to grow at a relatively higher CAGR
95% CI: 9.33 to 0.30
10.1016/j.ejphar.2009.12.023 84 McCleanP
[DOI] [PMC free article] [PubMed] [Google Scholar] 677.Verdich C., Flint A., Gutzwiller J.P., Naslund E., Beglinger C., Hellstrom P.M
The global Keytruda market is expected to achieve a CAGR of 8.9% from 2023 to 2032, with the valuation anticipated to reach $54 billion
2020;5:e140532
